Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Evans Discusses the Subgroup Analysis Results of the PREVAIL Study

May 20th 2014

Christopher P. Evans, MD, professor, chairman, Department of Urology, University of California at Davis School of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of an analysis of patients with and without visceral disease defined as liver and/or lung metastases who participated in the PREVAIL study.

Intermittent Degarelix Effective With Less Metabolic Syndrome Than Hormone Agonists, Studies Suggest

May 20th 2014

Men given the GnRH antagonist degarelix because their PSA level rose after primary therapy fared at least as well on an intermittent medication schedule as on a continuous schedule

Dr. Crawford on Intermittent Androgen Deprivation With Degarelix

May 20th 2014

E. David Crawford, MD, from University of Colorado at Denver, discusses a study presented at the 2014 AUA Annual Meeting that analyzed intermittent androgen deprivation with degarelix.

ED Therapy May Preserve Function, Penile Length After Prostatectomy

May 19th 2014

Daily treatment with the PDE-5 inhibitor tadalafil (Cialis) led to a significant decrease in loss of penile length among men who had undergone bilateral nerve-sparing radical prostatectomy.

In Dog Study, Prostate Cancer Found With a Whiff and a Woof

May 19th 2014

When it comes to detecting prostate cancer accurately and noninvasively, dogs may be ahead by a nose.

Active Surveillance Is No Threat to Prostate Cancer Cure-So Far

May 18th 2014

Prostate cancer patients who chose active surveillance did not compromise their chances of a cure by waiting before they underwent radical prostatectomy, data from a Swedish registry showed.

Dr. Beer on the Immune-Related Adverse Events of Ipilimumab in mCRPC

May 16th 2014

Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.

New NCCN Prostate Cancer Screening Guidelines Aim for Middle Ground

May 15th 2014

New prostate cancer screening guidelines that seek to balance overtreatment concerns with the need to preserve gains in curbing prostate cancer mortality were unveiled at the National Comprehensive Cancer Network's 19th Annual Conference.

Delaying ADT Until Symptoms Appear Does Not Impact Survival, Study Suggests

May 14th 2014

A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.

Immediate Surgery Improves Outcomes in Localized Prostate Cancer

May 13th 2014

A recent study that followed men newly diagnosed with localized prostate cancer for a median 18 years found that immediate radical prostatectomy significantly cut death rates as compared with watchful waiting with treatment upon progression, especially in men with intermediate-risk disease.

Studies Challenge Common Treatment Strategies in Prostate Cancer

May 8th 2014

Two recent studies have raised questions about current trends in prostate cancer (PC) treatment, one supporting the employment of a little-used strategy-direct treatment of the primary tumor in men who have metastatic PC at diagnosis

Vitamin E, Selenium Can Greatly Increase Prostate Cancer Risk

May 6th 2014

Despite being quite popular, the dietary supplements vitamin E and selenium do not protect men from developing prostate cancer, and in fact greatly increase risk in certain patients if taken at doses higher than those recommended

Dr. Yu on the Association of ALP With Outcomes in Patients With mCRPC

May 1st 2014

Evan Y. Yu, MD, from Seattle Cancer Care Alliance, discusses the association of alkaline phosphatase with outcomes in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

Dr. Dreicer on Trial Endpoints in Prostate Cancer

April 29th 2014

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

Custirsen Combination Misses Goal in Phase III mCRPC Trial

April 28th 2014

The combination of custirsen (OGX-011) with docetaxel and prednisone failed to significantly extend survival as a first-line treatment for men with metastatic castration-resistant prostate cancer

Dr. Petrylak on Imaging Approaches in Prostate Cancer

April 25th 2014

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, describes imaging approaches in prostate cancer

Dr. Pal on Sequencing Abiraterone and Enzalutamide in mCRPC

April 23rd 2014

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses the results of a retrospective analysis of the effect of prior abiraterone use on the activity level of enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Crawford Discusses Prostate Cancer Biopsies

April 22nd 2014

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses prostate cancer biopsies.

Dr. Sartor on Distinguishing Between Symptomatic and Asymptomatic Patients

April 16th 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Dr. Sartor on Distinguishing Between Symptomatic and Asymptomatic Patients

April 16th 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.